Research News

BrightFocus is funding a clinical trial to try to fight glaucoma with a new drug implanted in the eye that may protect the optic nerve.

BrightFocus Foundation today lauded a new, innovative citizen science project, EyesOnALZ, which recently launched an online game - Stall Catchers - to engage the public in helping researchers analyze Alzheimer’s data in the hopes of more quickly discovering ways to prevent and treat the disease.

BrightFocus Foundation, Geoffrey Beene Foundation Alzheimer’s Initiative, AnthroTronix, and Mindoula, have launched Phase II of the Health-eBrain Study, investigating the impact the Alzheimer’s caregiving experience has on brain and behavioral health.

Time magazine recently described a “cocktail” approach to fighting Alzheimer’s. BrightFocus-funded research supports this effort, which takes us closer to a cure.

Stacy Pagos Haller, BrightFocus Foundation's President and CEO, urges the Food and Drug Administration to strongly support expanded use of neurodiagnostic tools to assess cognitive function.

Download the fall edition of our macular degeneration research newsletter and read about new treatments that are on the horizon, the latest research grants awarded for pioneering macular degeneration research, the first-ever bionic eye for patients with macular degeneration, and more.

In a major scientific breakthrough, a drug used to treat Parkinson’s and related diseases may be able to delay or prevent age-related macular degeneration (AMD), the most common form of blindness among older Americans.